BioNTech SE
BioNTech SE's Overview
BioNTech SE (Biopharmaceutical New Technologies) is a global biotechnology company headquartered in Mainz, Germany, focused on pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. BioNTech is globally recognized for its pivotal role in developing the first widely approved mRNA-based COVID-19 vaccine in partnership with Pfizer.
Where is BioNTech SE's Headquarters?
HQ Function
The Mainz headquarters serves as the central hub for BioNTech's research and development, corporate operations, and strategic decision-making. It houses state-of-the-art laboratories and administrative offices.
Notable Features:
The headquarters features advanced research facilities, including GMP (Good Manufacturing Practice) certified manufacturing sites for clinical trial materials and commercial production. The campus is designed to foster collaboration and innovation.
Work Culture:
BioNTech promotes a dynamic, science-driven, and collaborative work culture. Employees are highly motivated by the company's mission to develop groundbreaking therapies. The environment is characterized by innovation, agility, and a commitment to excellence.
HQ Significance:
The Mainz headquarters is significant as the birthplace of BioNTech's innovative mRNA technology and the central command for its global operations, including the development of the Pfizer-BioNTech COVID-19 vaccine.
Values Reflected in HQ: The headquarters reflects BioNTech's core values of innovation, scientific rigor, patient focus, and collaboration, evident in its advanced R&D infrastructure, sustainable building practices, and collaborative workspaces.
Location:
BioNTech SE supports a wide range of functions globally, including research and development across various therapeutic platforms (mRNA, cell therapies, antibodies, AI-driven drug discovery), clinical trial operations in numerous countries, GMP-certified manufacturing and supply chain management, business development, and commercial operations. Its collaborations and partnerships extend worldwide, enabling a global reach for its innovative medicines.
Street Address:
An der Goldgrube 12
City:
Mainz
State/Province:
Rhineland-Palatinate
Country:
Germany
BioNTech SE's Global Presence
Cambridge, Massachusetts, USA
Address: 40 Erie Street, Suite 110, Cambridge, MA 02139, USA
Facilitates collaboration with U.S. academic institutions, research partners, and regulatory bodies like the FDA. Drives clinical trial execution and commercial strategy for the U.S. market.
Marburg, Hesse, Germany
Address: Emil-von-Behring-Straße 76, 35041 Marburg, Germany
Key node in BioNTech's global manufacturing network, ensuring supply of vaccines and other therapeutics for Europe and worldwide distribution. Enhances production capacity and flexibility.
Gaithersburg, Maryland, USA
Address: 9500 Medical Center Dr, Rockville, MD 20850, USA
Strengthens BioNTech's presence in the U.S. cell therapy landscape, providing critical infrastructure for advancing its pipeline of innovative cancer treatments.
London, United Kingdom
Address: Multiple locations including operations from the InstaDeep acquisition, e.g., near Broadgate, London.
Integrates cutting-edge AI/ML capabilities into BioNTech's global operations, aiming to accelerate the development of novel immunotherapies and optimize various aspects of the biopharmaceutical value chain.
Buying Intent Signals for BioNTech SE
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of BioNTech SE
As of April 2025, BioNTech SE' leadership includes:
Investors of BioNTech SE
BioNTech SE has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
BioNTech has experienced notable executive team transitions over the past 12 months, including the departure of its Chief Operating Officer and the strategic appointments of a new Chief Legal Officer and a new Chief Commercial Officer, reflecting the company's ongoing evolution and focus on future growth.
Departures
New Appointments:
Technology (Tech Stack) used by BioNTech SE
Discover the tools BioNTech SE uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
BioNTech SE Email Formats and Examples
BioNTech SE primarily uses the email format [first].[last]@biontech.de. Variations such as [first_initial][last]@biontech.de may also exist, particularly for common names or specific departments. The domain used is typically @biontech.de.
first.last@biontech.de
Format
ugur.sahin@biontech.de
Example
85%
Success rate
News and media
Reuters • June 4, 2024
BioNTech SE news: BioNTech shares fall after mixed early data on cancer vaccine candidate
BioNTech shares declined after the company presented early trial data for its experimental cancer vaccine candidate, BNT122 (autogene cevumeran), at the ASCO meeting, showing mixed results in treating pancreatic cancer and colorectal cancer....more
BioNTech Press Release • May 6, 2024
BioNTech SE news: BioNTech Reports First Quarter 2024 Financial Results and Corporate Update
BioNTech announced its financial results for Q1 2024, reporting revenues of €187.6 million and a net loss. The company highlighted progress in its oncology pipeline, including advancements in ADC and mRNA cancer vaccine candidates, and reiterated its focus on launching its first oncology product by 2026....more
Fierce Biotech • June 3, 2024
BioNTech SE news: ASCO: BioNTech's Roche-partnered cancer vaccine shows long-term promise in pancreatic cancer
BioNTech and Roche's individualized mRNA cancer vaccine, autogene cevumeran, demonstrated sustained T-cell activity and delayed tumor recurrence in a subset of pancreatic cancer patients in a Phase 1 trial, according to data presented at the American Society of Clinical Oncology (ASCO) annual meeting....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including BioNTech SE, are just a search away.